XJPX9776
Market cap20mUSD
Jan 07, Last price
980.00JPY
1D
0.93%
1Q
2.30%
Jan 2017
-16.52%
Name
Sapporo Clinical Laboratory Inc
Chart & Performance
P/E
8.59
P/S
0.17
EPS
114.14
Div Yield, %
2.34%
Shrs. gr., 5y
—
Rev. gr., 5y
0.47%
Revenues
19.68b
-2.21%
Net income
380m
-33.14%
CFO
1.08b
-24.66%
Dividend
Mar 28, 20250 JPY/sh
Profile
Sapporo Clinical Laboratory Inc. operates dispensing pharmacies in Japan. The company offers clinical examination, pathological examination, and holter examination services. It provides food hygiene environmental inspection, including food/processed product, facility hygiene, and food handler inspection services; and radiation management services. In addition, the company develops, sells, and maintains software, such as SCAN clinical testing systems; and offers support services for opening new clinics. Further, it provides HiWeb21 inspection result inquiry services, as well as sells and maintains software relating to clinical testing. The company was incorporated in 1965 and is based in Sapporo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 19,682,319 -2.21% | 20,127,692 5.33% | 19,109,595 9.18% | ||
Cost of revenue | 18,346,898 | 13,977,454 | 12,939,738 | ||
Unusual Expense (Income) | |||||
NOPBT | 1,335,421 | 6,150,238 | 6,169,857 | ||
NOPBT Margin | 6.78% | 30.56% | 32.29% | ||
Operating Taxes | 234,995 | 319,148 | 455,601 | ||
Tax Rate | 17.60% | 5.19% | 7.38% | ||
NOPAT | 1,100,426 | 5,831,090 | 5,714,256 | ||
Net income | 380,156 -33.14% | 568,619 -45.48% | 1,042,882 31.40% | ||
Dividends | (76,531) | (77,048) | (78,604) | ||
Dividend yield | 2.12% | 1.82% | 1.78% | ||
Proceeds from repurchase of equity | (29,214) | (95,028) | |||
BB yield | 0.69% | 2.15% | |||
| Debt | |||||
Debt current | 260,445 | 261,294 | 239,733 | ||
Long-term debt | 2,536,068 | 2,865,083 | 3,060,318 | ||
Deferred revenue | 178,645 | ||||
Other long-term liabilities | 241,428 | 20,488 | 186,395 | ||
Net debt | (1,390,109) | (856,122) | (42,104) | ||
| Cash flow | |||||
Cash from operating activities | 1,077,593 | 1,430,350 | 1,573,628 | ||
CAPEX | (388,000) | (825,906) | (948,369) | ||
Cash from investing activities | (395,474) | (409,028) | (830,960) | ||
Cash from financing activities | (369,961) | (347,894) | (112,738) | ||
FCF | 1,179,968 | 6,055,127 | 4,750,696 | ||
| Balance | |||||
Cash | 3,976,239 | 3,664,081 | 2,990,653 | ||
Long term investments | 210,383 | 318,418 | 351,502 | ||
Excess cash | 3,202,506 | 2,976,114 | 2,386,675 | ||
Stockholders' equity | 10,837,474 | 10,623,122 | 10,051,699 | ||
Invested Capital | 10,419,823 | 10,443,709 | 10,426,656 | ||
ROIC | 10.55% | 55.88% | 57.64% | ||
ROCE | 9.79% | 45.77% | 48.15% | ||
| EV | |||||
Common stock shares outstanding | 3,330 | 3,334 | 3,406 | ||
Price | 1,082.00 -14.60% | 1,267.00 -2.24% | 1,296.00 -15.40% | ||
Market cap | 3,603,060 -14.70% | 4,224,178 -4.30% | 4,414,176 -15.82% | ||
EV | 2,459,337 | 3,663,644 | 4,595,731 | ||
EBITDA | 1,871,014 | 6,669,334 | 6,716,861 | ||
EV/EBITDA | 1.31 | 0.55 | 0.68 | ||
Interest | 7,492 | 8,168 | 9,027 | ||
Interest/NOPBT | 0.56% | 0.13% | 0.15% | ||